Scott Daniels joined Inotiv in March 2019 as the senior vice president of drug metabolism and pharmacokinetics (DMPK). He is an accomplished executive in pharmaceutical research and development and brings over 15 years of experience and leadership to the company.
Daniels has advanced the fields of biotransformation and drug metabolism at DuPont Pharmaceuticals, Millennium, Pfizer, and Precera Bioscience, publishing in areas of drug metabolism, chemical toxicology, and pharmacology. Prior to joining Inotiv, Daniels was chief scientific officer at Precera Bioscience and director of drug metabolism and pharmacokinetics at the Center for Neuroscience Drug Discovery at Vanderbilt School of Medicine, where he is currently an adjunct professor of pharmacology. He also is an advisory committee member of the Cleveland Clinic Center for Therapeutics Discovery. He received his undergraduate degree in biology and chemistry from Southwest Baptist University and his doctorate in chemistry from the University of Missouri-Columbia and performed his post-doctoral research in chemical toxicology at Vanderbilt University Medical Center.